Neoadjuvant treatment of soft-tissue sarcoma: A multimodality approach

David Reynoso, Vivek Subbiah, Jonathan C. Trent, B. Ashleigh Guadagnolo, Alexander J. Lazar, Robert Benjamin, Raphael E. Pollock, Joseph A. Ludwig

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Unlike epithelial cancers that are both more homogeneous and easily categorized by their respective tissues of origin (e.g., breast or lung cancer), sarcomas represent a diverse class of molecularly distinct bone and soft-tissue mesenchymal neoplasms of more than 50 subtypes. This diversity, as well as the relative rarity of sarcomas as a whole, has presented challenges in conducting prospective randomized clinical trials to assess the value of neoadjuvant chemotherapy for any given subtype. Most clinical trials and meta-analyses have neglected the phenotypic and molecular heterogeneity differentiating one sarcoma subtype from another in favor of a simplified grouping that ensures timely trial completion. As the success of treating gastrointestinal stromal tumors (GISTs) with imatinib demonstrates, a decision to provide neoadjuvant chemotherapy must take into consideration both the subtype being treated and the effect such treatment would be expected to exert upon that subtype.

Original languageEnglish (US)
Pages (from-to)327-333
Number of pages7
JournalJournal of Surgical Oncology
Volume101
Issue number4
DOIs
StatePublished - Mar 15 2010
Externally publishedYes

Fingerprint

Neoadjuvant Therapy
Sarcoma
Soft Tissue Neoplasms
Drug Therapy
Gastrointestinal Stromal Tumors
Meta-Analysis
Lung Neoplasms
Randomized Controlled Trials
Clinical Trials
Breast Neoplasms
Bone and Bones
Neoplasms
Therapeutics

Keywords

  • Adjuvant
  • Biomarkers
  • Cancer
  • Chemotherapy
  • Surgery
  • Survival

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Reynoso, D., Subbiah, V., Trent, J. C., Guadagnolo, B. A., Lazar, A. J., Benjamin, R., ... Ludwig, J. A. (2010). Neoadjuvant treatment of soft-tissue sarcoma: A multimodality approach. Journal of Surgical Oncology, 101(4), 327-333. https://doi.org/10.1002/jso.21481

Neoadjuvant treatment of soft-tissue sarcoma : A multimodality approach. / Reynoso, David; Subbiah, Vivek; Trent, Jonathan C.; Guadagnolo, B. Ashleigh; Lazar, Alexander J.; Benjamin, Robert; Pollock, Raphael E.; Ludwig, Joseph A.

In: Journal of Surgical Oncology, Vol. 101, No. 4, 15.03.2010, p. 327-333.

Research output: Contribution to journalReview article

Reynoso, D, Subbiah, V, Trent, JC, Guadagnolo, BA, Lazar, AJ, Benjamin, R, Pollock, RE & Ludwig, JA 2010, 'Neoadjuvant treatment of soft-tissue sarcoma: A multimodality approach', Journal of Surgical Oncology, vol. 101, no. 4, pp. 327-333. https://doi.org/10.1002/jso.21481
Reynoso D, Subbiah V, Trent JC, Guadagnolo BA, Lazar AJ, Benjamin R et al. Neoadjuvant treatment of soft-tissue sarcoma: A multimodality approach. Journal of Surgical Oncology. 2010 Mar 15;101(4):327-333. https://doi.org/10.1002/jso.21481
Reynoso, David ; Subbiah, Vivek ; Trent, Jonathan C. ; Guadagnolo, B. Ashleigh ; Lazar, Alexander J. ; Benjamin, Robert ; Pollock, Raphael E. ; Ludwig, Joseph A. / Neoadjuvant treatment of soft-tissue sarcoma : A multimodality approach. In: Journal of Surgical Oncology. 2010 ; Vol. 101, No. 4. pp. 327-333.
@article{95dfd8ce8caf4ebd90b98f0293c6835d,
title = "Neoadjuvant treatment of soft-tissue sarcoma: A multimodality approach",
abstract = "Unlike epithelial cancers that are both more homogeneous and easily categorized by their respective tissues of origin (e.g., breast or lung cancer), sarcomas represent a diverse class of molecularly distinct bone and soft-tissue mesenchymal neoplasms of more than 50 subtypes. This diversity, as well as the relative rarity of sarcomas as a whole, has presented challenges in conducting prospective randomized clinical trials to assess the value of neoadjuvant chemotherapy for any given subtype. Most clinical trials and meta-analyses have neglected the phenotypic and molecular heterogeneity differentiating one sarcoma subtype from another in favor of a simplified grouping that ensures timely trial completion. As the success of treating gastrointestinal stromal tumors (GISTs) with imatinib demonstrates, a decision to provide neoadjuvant chemotherapy must take into consideration both the subtype being treated and the effect such treatment would be expected to exert upon that subtype.",
keywords = "Adjuvant, Biomarkers, Cancer, Chemotherapy, Surgery, Survival",
author = "David Reynoso and Vivek Subbiah and Trent, {Jonathan C.} and Guadagnolo, {B. Ashleigh} and Lazar, {Alexander J.} and Robert Benjamin and Pollock, {Raphael E.} and Ludwig, {Joseph A.}",
year = "2010",
month = "3",
day = "15",
doi = "10.1002/jso.21481",
language = "English (US)",
volume = "101",
pages = "327--333",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Neoadjuvant treatment of soft-tissue sarcoma

T2 - A multimodality approach

AU - Reynoso, David

AU - Subbiah, Vivek

AU - Trent, Jonathan C.

AU - Guadagnolo, B. Ashleigh

AU - Lazar, Alexander J.

AU - Benjamin, Robert

AU - Pollock, Raphael E.

AU - Ludwig, Joseph A.

PY - 2010/3/15

Y1 - 2010/3/15

N2 - Unlike epithelial cancers that are both more homogeneous and easily categorized by their respective tissues of origin (e.g., breast or lung cancer), sarcomas represent a diverse class of molecularly distinct bone and soft-tissue mesenchymal neoplasms of more than 50 subtypes. This diversity, as well as the relative rarity of sarcomas as a whole, has presented challenges in conducting prospective randomized clinical trials to assess the value of neoadjuvant chemotherapy for any given subtype. Most clinical trials and meta-analyses have neglected the phenotypic and molecular heterogeneity differentiating one sarcoma subtype from another in favor of a simplified grouping that ensures timely trial completion. As the success of treating gastrointestinal stromal tumors (GISTs) with imatinib demonstrates, a decision to provide neoadjuvant chemotherapy must take into consideration both the subtype being treated and the effect such treatment would be expected to exert upon that subtype.

AB - Unlike epithelial cancers that are both more homogeneous and easily categorized by their respective tissues of origin (e.g., breast or lung cancer), sarcomas represent a diverse class of molecularly distinct bone and soft-tissue mesenchymal neoplasms of more than 50 subtypes. This diversity, as well as the relative rarity of sarcomas as a whole, has presented challenges in conducting prospective randomized clinical trials to assess the value of neoadjuvant chemotherapy for any given subtype. Most clinical trials and meta-analyses have neglected the phenotypic and molecular heterogeneity differentiating one sarcoma subtype from another in favor of a simplified grouping that ensures timely trial completion. As the success of treating gastrointestinal stromal tumors (GISTs) with imatinib demonstrates, a decision to provide neoadjuvant chemotherapy must take into consideration both the subtype being treated and the effect such treatment would be expected to exert upon that subtype.

KW - Adjuvant

KW - Biomarkers

KW - Cancer

KW - Chemotherapy

KW - Surgery

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=77749240348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77749240348&partnerID=8YFLogxK

U2 - 10.1002/jso.21481

DO - 10.1002/jso.21481

M3 - Review article

C2 - 20187067

AN - SCOPUS:77749240348

VL - 101

SP - 327

EP - 333

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 4

ER -